Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (231-240 of 596) with videos related to

Pageof 60
Sort By:
PLOS Digital Health|March 15, 2023
Explainable AI identifies diagnostic cells of genetic AML subtypesMatthias Hehr, Ario Sadafi, Christian Matek, et al.
Leukemia|June 8, 2026
Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosisJana Wobst, Marietta Truger, Natalie Wossidlo, et al.
British Journal of Haematology|July 24, 2010
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasmsLena Reindl, Ulrike Bacher, Frank Dicker, et al.
Blood|December 15, 2010
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosisSusanne Schnittger, Frank Dicker, Wolfgang Kern, et al.
Blood Advances|November 21, 2018
<i>NPM1</i> mutated AML can relapse with wild-type <i>NPM1</i>: persistent clonal hematopoiesis can drive relapseAlexander Höllein, Manja Meggendorfer, Frank Dicker, et al.
Cancer Gene Therapy|February 11, 2022
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesisHeiko Müller, Wencke Walter, Stephan Hutter, et al.
Haematologica|August 30, 2012
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasmsSabine Jeromin, Torsten Haferlach, Vera Grossmann, et al.
Blood|May 16, 2014
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosisAnna Stengel, Susanne Schnittger, Sandra Weissmann, et al.
Leukemia|September 28, 2024
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phaseWencke Walter, Niroshan Nadarajah, Stephan Hutter, et al.
British Journal of Haematology|August 20, 2014
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemiaMarietta S Truger, Sabine Jeromin, Sandra Weissmann, et al.
Pageof 60

Showing results (231-240 of 596) with videos related to

Sort By:
Pageof 60
PLOS Digital Health|March 15, 2023
Explainable AI identifies diagnostic cells of genetic AML subtypesMatthias Hehr, Ario Sadafi, Christian Matek, et al.
Leukemia|June 8, 2026
Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosisJana Wobst, Marietta Truger, Natalie Wossidlo, et al.
British Journal of Haematology|July 24, 2010
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasmsLena Reindl, Ulrike Bacher, Frank Dicker, et al.
Blood|December 15, 2010
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosisSusanne Schnittger, Frank Dicker, Wolfgang Kern, et al.
Blood Advances|November 21, 2018
<i>NPM1</i> mutated AML can relapse with wild-type <i>NPM1</i>: persistent clonal hematopoiesis can drive relapseAlexander Höllein, Manja Meggendorfer, Frank Dicker, et al.
Cancer Gene Therapy|February 11, 2022
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesisHeiko Müller, Wencke Walter, Stephan Hutter, et al.
Haematologica|August 30, 2012
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasmsSabine Jeromin, Torsten Haferlach, Vera Grossmann, et al.
Blood|May 16, 2014
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosisAnna Stengel, Susanne Schnittger, Sandra Weissmann, et al.
Leukemia|September 28, 2024
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phaseWencke Walter, Niroshan Nadarajah, Stephan Hutter, et al.
British Journal of Haematology|August 20, 2014
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemiaMarietta S Truger, Sabine Jeromin, Sandra Weissmann, et al.
Pageof 60